How Effective Is Hydroxychloroquine for Sjogren’s?

Hydroxychloroquine has not been shown to meaningfully improve the core symptoms of Sjögren’s syndrome in rigorous clinical trials. The largest and most influential randomized trial found that it performed no better than a placebo for dryness, fatigue, or pain after six months of treatment. Yet the drug remains one of the most commonly prescribed medications for the disease, taken by an estimated quarter to half of patients. That gap between the evidence and clinical practice is worth understanding in detail, because the story is more nuanced than a simple “it doesn’t work.”

What the Largest Trial Actually Found

The trial that reshaped the conversation around hydroxychloroquine (HCQ) in Sjögren’s was the JOQUER study, a French randomized, placebo-controlled trial published in JAMA in 2014. After 24 weeks of treatment, roughly 18% of patients in the HCQ group met the primary endpoint for symptom improvement, compared with about 17% in the placebo group. The difference was essentially zero. HCQ also showed no advantage in patients who had anti-SSA autoantibodies, elevated immunoglobulin G levels, or systemic disease involvement.¹

This was a well-designed study, and its conclusion was blunt: HCQ did not improve symptoms. For many rheumatologists and patients, this was a deflating result. Before JOQUER, HCQ had been prescribed for Sjögren’s largely on the basis of clinical experience, smaller open-label studies, and the logic that a drug effective in lupus should help in a related autoimmune condition. JOQUER challenged that assumption head-on.

Where It Does Seem to Help, at Least on Paper

The picture shifts when you move away from patient-reported symptoms and look at laboratory markers of inflammation instead. A systematic review and meta-analysis found that HCQ treatment was associated with reductions in erythrocyte sedimentation rate (a general inflammation marker), C-reactive protein, and immunoglobulin levels compared with placebo.² An earlier trial from the late 1980s had similarly found that HCQ lowered total IgG and IgA levels, decreased rheumatoid factor, and brought down sedimentation rate while raising hemoglobin levels.³

This creates an odd situation. The drug appears to dial down immune overactivity as measured by blood tests, but those changes don’t translate into patients feeling noticeably better. It’s a reminder that normalizing a lab value and relieving a symptom are not the same thing. Some clinicians view the lab improvements as evidence that HCQ could slow disease progression or prevent complications over the long term, but that hypothesis has not been tested in a large prospective trial.

One area where the meta-analysis data looked somewhat more favorable was pain. Pooled results showed that HCQ-treated patients reported better pain outcomes than those on placebo, though the effect was modest.⁴ For dry mouth and dry eyes, HCQ was essentially no different from placebo, with response rates hovering around 48% for HCQ versus 43–46% for placebo on dryness measures.

The Fatigue Problem

Fatigue is often described as the single most debilitating symptom of Sjögren’s, worse than the dryness for many patients. Unfortunately, HCQ does not appear to help with it, and some analyses suggest the drug may actually perform worse than placebo on fatigue measures.⁴ A meta-analysis that included a double-blind crossover trial and a larger randomized trial found no benefit for fatigue severity.

The evidence is not entirely one-sided. A retrospective study of over 200 patients found that fatigue was reported far less frequently among those on HCQ than those not taking it.⁵ But retrospective studies carry well-known biases: patients who tolerate a drug and feel it is helping are more likely to stay on it, inflating apparent benefits. The controlled trial data carries more weight, and it does not support HCQ for fatigue.

Why Doctors Keep Prescribing It Anyway

If the evidence is this weak, why is HCQ still so widely used? A 2024 review in Joint Bone Spine put it plainly: although HCQ is recommended in international guidelines and widely prescribed for Sjögren’s, its use is mostly based on expert opinion and personal experience rather than strong clinical trial data.⁶

Several factors explain the persistence. Sjögren’s has very few approved drug treatments, so clinicians work with what they have. HCQ is inexpensive, generally well tolerated in the short to medium term, and has a long track record in lupus, which shares immunological features with Sjögren’s. Many rheumatologists feel that even if the symptom benefit is marginal, the anti-inflammatory effects on lab markers justify its use as a kind of background immunomodulator. There’s also a pragmatic calculus: if a patient has overlapping features of lupus and Sjögren’s, HCQ is clearly indicated for the lupus component, and any benefit for Sjögren’s symptoms is a bonus.

None of this makes HCQ an evidence-based treatment for Sjögren’s symptoms in the traditional sense. It does mean the decision to try it is not irrational, especially when alternatives are limited.

Could It Work for Some Patients and Not Others?

One of the more intriguing follow-ups to the JOQUER trial involved going back to the data and splitting patients into subgroups based on their symptom profiles. When researchers stratified the original JOQUER participants by whether they had high or low symptom burden, both subgroups appeared to show some response to HCQ, even though the overall trial result was negative.⁷ This kind of post-hoc subgroup analysis is hypothesis-generating, not proof of anything, but it suggests the flat “no effect” conclusion may obscure real variation in who responds.

Research into predictive biomarkers is building on this idea. One study found that salivary gland expression levels of a protein called LAMP3 could potentially predict who would benefit from HCQ. Patients with high LAMP3 expression tended to show better improvement in disease activity scores and symptom severity when treated with HCQ, compared with those who had normal LAMP3 levels.⁸ This matters because LAMP3 is tied directly to the type I interferon pathway that drives much of the gland inflammation in Sjögren’s.

How HCQ Relates to What Goes Wrong in Sjögren’s

The immune system disruption in Sjögren’s involves, among other things, overactive signaling through receptors called Toll-like receptors (TLRs), particularly TLR-7. In patients with primary Sjögren’s, TLR-7 is overexpressed in the salivary glands, both in immune cells that have infiltrated the gland tissue and in the duct cells themselves. This triggers production of type I interferons, inflammatory signaling molecules that perpetuate gland damage.⁹ Research has also identified a feedback loop in which LAMP3 protein in salivary gland cells promotes TLR-7 expression, which in turn boosts interferon production, which then drives more LAMP3, keeping the cycle going.¹⁰

HCQ is known to block endosomal TLR signaling, which is part of why it works in lupus. It interferes with TLR-7 and TLR-9 activation by changing how nucleic acids interact with these receptors inside immune cells.¹¹ In theory, this should dampen the interferon-driven inflammation in Sjögren’s salivary glands. In practice, the gland damage in Sjögren’s may already be too established by the time patients are diagnosed for TLR blockade alone to reverse symptoms. The drug might be doing something at the immune level without generating enough tissue recovery for the patient to notice.

The Leflunomide Combination

If HCQ alone is underwhelming, could combining it with another immunomodulator do more? A placebo-controlled trial tested the combination of leflunomide (a drug used in rheumatoid arthritis) with HCQ in patients with Sjögren’s who had systemic disease activity. After 24 weeks, the combination group showed a clinically meaningful reduction in disease activity scores, with an adjusted difference of about 4.4 points on the ESSDAI scale compared with placebo. No serious adverse events occurred in the treatment group.¹²

This was a small phase II trial and needs to be replicated, but it represents one of the more encouraging signals in recent Sjögren’s treatment research. Researchers working with this combination have also identified blood proteins, specifically CXCL10 and CXCL11, that at baseline could distinguish patients who went on to respond from those who did not.¹³ Another analysis from the same trial found that decreases in circulating levels of galectin-9 and a protein called MxA were associated with clinical response.¹⁴ If these biomarkers hold up in larger studies, they could eventually allow clinicians to identify which patients are likely to benefit before committing to months of treatment.

Eye Risks with Long-Term Use

HCQ’s best-known safety concern is retinal toxicity. The drug can accumulate in the retina over years and cause irreversible damage to central vision. Current guidelines recommend keeping the daily dose at or below 5 mg per kilogram of actual body weight to minimize this risk, and the evidence supports this threshold. Multiple studies have found that higher daily dosing relative to real body weight, longer duration of therapy, and greater cumulative exposure all increase the chance of toxicity.¹⁵

A study of 80 patients on long-term HCQ found that about 9% had definite retinopathy and another 10% had possible retinopathy. Nearly all patients with confirmed retinal damage had been taking more than 6 mg/kg/day, exceeding the recommended limit. Most had also been on the drug for over a decade.¹⁶ The practical takeaway is that the risk is low in the first five years at appropriate doses but climbs meaningfully after that. Regular eye screening, typically starting after five years of use, is standard practice for anyone on HCQ.

For Sjögren’s patients specifically, this creates an uncomfortable question. If the symptom benefit of HCQ is marginal at best, is it worth taking a drug for years or decades that carries a real, cumulative risk to your vision? The answer depends on why you’re taking it. If HCQ is managing overlapping lupus features or keeping inflammatory markers in check, the risk-benefit calculation may favor staying on it. If it was prescribed empirically and you’ve never noticed a clear benefit, it’s a conversation worth having with your rheumatologist.

Other Safety Considerations

Retinal toxicity gets the most attention, but HCQ can affect other organs as well. Case reports and reviews have documented cardiac toxicity, including cardiomyopathy, in some patients on chronic HCQ therapy. A case series found that catastrophic adverse events, including cardiac complications, occurred even in patients whose doses fell within the recommended weight-based range, raising questions about whether weight-based dosing alone is sufficient to ensure safety.¹⁷ These events are uncommon, but they underscore that HCQ is not as benign as its reputation sometimes suggests, particularly with prolonged use.

Gastrointestinal side effects are the most common complaint in practice: nausea, stomach cramps, and occasionally diarrhea. These are usually manageable and often improve after the first few weeks. Skin reactions, including pigmentation changes, occur occasionally. For most patients, these nuisances are tolerable, but the calculus changes when the drug isn’t clearly doing much for their primary complaint.

Where Sjögren’s Treatment Is Heading

The interest in biomarker-guided therapy reflects a broader shift in how researchers think about Sjögren’s. Rather than treating all patients the same way and hoping for the best, the field is moving toward stratifying patients by their molecular profiles. The LAMP3-interferon feedback loop in salivary glands is one example of a pathway that could identify patients more likely to respond to TLR-targeting drugs like HCQ.⁸ The identification of CXCL10 and CXCL11 as potential predictors for the leflunomide-HCQ combination similarly points toward a future where treatment choices are guided by blood tests rather than trial and error.¹³

Biologic therapies targeting B cells, interferons, and other specific immune pathways are also under active investigation for Sjögren’s. Rituximab, which depletes B cells, has been studied in early disease with mixed results. Other agents targeting the interferon pathway more directly than HCQ does are in various stages of development. For now, though, HCQ remains in the toolkit, not because the evidence for it is strong, but because the alternatives are still being proven and because the drug does appear to quiet the immune system in measurable ways, even if patients rarely feel a dramatic difference.